Artiria Medical has announced the successful closing of a Series A2 round worth US$6 million and the securing of a US$600,000 Fit Tech Growth loan.
The Series A2 investment round, led by 4FOX Ventures, was joined by the Wyss Center for Bio and Neuroengineering (Geneva, Switzerland), and existing investors including Verve Ventures, the Zürcher Kantonalbank, NEST pension fund, and business angels.
Related: Pharyngeal neurostim company Phagenesis raises $42M
“This funding round shall enable Artiria to study the unique features of our product with key opinion leaders in both Europe and the USA through a randomised controlled study against the market-leading products,” said Guillaume Petit-Pierre, chief executive officer and co-founder of Artiria.
“Following the already-secured FDA [Food and Drug Administration] clearance, this study will further enable Artiria to apply for European market approval, thus significantly extending the scope of the company,” added Valentin Chenaux, general partner of 4FOX Ventures. “We believe that Artiria’s innovative solution will advance the treatment of stroke with a product enabling safe yet accelerated procedures, and we are delighted to be part of this great journey.”
Artiria develops next-generation neurointerventional technologies for treating stroke and brain aneurysms, and its leading product is a novel real-time deflectable guidewire that is designed to enable surgeons to access diseased neurovascular sites faster. This product has already been used in humans, with the first patients being treated in the third quarter of 2023.
